前瞻性计算机模拟研究:比较标准IMRT,评估MRI引导剂量自适应策略用于人乳头瘤病毒阳性口咽癌患者的可行性与剂量学优势
本研究纳入5例局部晚期HPV阳性口咽鳞癌患者,在放疗期间每两周行MRI并生成标准与自适应IMRT计划。自适应计划降低了95%初始PTV平均剂量及多数危及器官剂量参数,尤其吞咽相关结构,吞咽困难≥2级、6个月喂养管依赖和1年甲状腺功能减退概率分别平均降低11%、4%和5%。
要点
- 自适应计划使95%初始PTV平均剂量由70.7 Gy降至58.5 Gy。
- 自适应计划多数危及器官剂量参数下降,吞咽肌群尤为明显。
- 吞咽困难≥2级、6个月喂养管依赖和1年甲状腺功能减退概率分别平均降低11%、4%和5%。
核心结论
- 这些计算机模拟结果表明,所提出的MRI引导自适应方法在技术上是可行的,并具有降低危及器官剂量的优势,尤其是吞咽肌群。
研究设计与样本
- 前瞻性计算机模拟(in silico)研究,纳入5例局部晚期HPV阳性口咽鳞癌患者,每两周在放疗固定装置下行治疗前及治疗中MRI,为每例患者创建标准与自适应两种IMRT计划。
主要发现
- 标准计划对初始PTV的处方剂量为2.12 Gy/次、共33次。
- 自适应计划中,若系列MRI可检测到肿瘤缩小则生成新的PTVadaptive,处方剂量为2.12 Gy/次,以使残留病灶获得最大剂量;既往受累体积最低接受50.16 Gy;未受累选择性淋巴结体积处方50.16 Gy、1.52 Gy/次。
- 95%初始PTV体积的平均剂量为标准计划70.7 Gy(SD,0.3)vs 自适应计划58.5 Gy(SD,2.0)。
- 自适应计划较标准计划多数危及器官剂量参数下降,尤其是吞咽相关结构。
- 发生吞咽困难≥2级、治疗后6个月喂养管持续依赖和治疗后1年甲状腺功能减退的概率平均分别降低11%、4%和5%;自适应计划较标准IMRT,6个月口干概率仅降低1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为纳入5例患者的先导研究。
- 这些为计算机模拟结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aim to determine the feasibility and dosimetric benefits of a novel MRI-guided IMRT dose-adaption strategy for human papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPC). MATERIALS/METHODS: Patients with locally advanced HPV+ OPC underwent pre-treatment and in-treatment MRIs every two weeks using RT immobilization setup. For each patient, two IMRT plans were created (i.e. standard and adaptive). The prescription dose for the standard plans was 2.12 Gy/fx for 33 fractions to the initial PTV. For adaptive plans, a new PTVadaptive was generated based on serial MRIs in case of detectable tumor shrinkage. Prescription dose to PTVadaptive was 2.12 Gy/fx to allow for maximum dose to the residual disease. Any previously involved volumes received minimally a floor dose of 50.16 Gy. Uninvolved elective nodal volumes were prescribed 50.16 Gy in 1.52 Gy/fx. Dosimetric parameters of organs at risk (OARs) were recorded for standard vs. adaptive plans. Normal tissue complication probability (NTCP) for toxicity endpoints was calculated using literature-derived multivariate logistic regression models. RESULTS: Five patients were included in this pilot study, 3 men and 2 women. Median age was 58 years (range 45-69). Three tumors originated at the tonsillar fossa and two at the base of tongue. The average dose to 95% of initial PTV volume was 70.7 Gy (SD,0.3) for standard plans vs. 58.5 Gy (SD,2.0) for adaptive plans. The majority of OARs showed decrease in dosimetric parameters using adaptive plans vs. standard plans, particularly swallowing related structures. The average reduction in the probability of developing dysphagia ≥ grade2, feeding tube persistence at 6-month post-treatment and hypothyroidism at 1-year post-treatment was 11%, 4%, and 5%, respectively. The probability of xerostomia at 6-month was only reduced by 1% for adaptive plans vs. standard IMRT. CONCLUSION: These in silico results showed that the proposed MRI-guided adaptive approach is technically feasible and advantageous in reducing dose to OARs, especially swallowing musculature.
引用
- Mohamed ASR, Bahig H, Aristophanous M, et al. Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. Clin Transl Radiat Oncol. 2018. PMID: 30014042. doi:10.1016/j.ctro.2018.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。